{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:58Z","timestamp":1772121058497,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002141","name":"UK Health Security Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jinf.2022.01.038","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:00:45Z","timestamp":1643972445000},"page":"692-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-4471","authenticated-orcid":false,"given":"Samantha J","family":"Westrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel A","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Whillock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-8917","authenticated-orcid":false,"given":"Helen","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-0146","authenticated-orcid":false,"given":"Ruth","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenesha","family":"Warrener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamez N","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-683X","authenticated-orcid":false,"given":"Kevin E","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Amirthalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2022.01.038_bib0001","unstructured":"GAVI The Vaccine Alliance. The COVID-19 vaccine race - weekly update. [Online] 20 October 2021. [Cited: 21 10 2021.] https:\/\/www.gavi.org\/vaccineswork\/covid-19-vaccine-race?gclid=Cj0KCQjwqp-LBhDQARIsAO0a6aKxB6hoNZQPd83kb-YZFbeVK7D46TFsTTJShOBqEARWhaepPMi5JIGEaAjNeEALw_wcB."},{"key":"10.1016\/j.jinf.2022.01.038_bib0002","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jinf.2022.01.038_bib0003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0004","unstructured":"Public Health England. COVID-19: the green book, chapter 14a. 2020. Coronavirus (COVID-19) vaccination information for public health professionals."},{"key":"10.1016\/j.jinf.2022.01.038_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-021-01359-3","article-title":"Mix-and-match COVID vaccines trigger potent immune response","volume":"593","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jinf.2022.01.038_bib0006","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100634","article-title":"Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March\u2212June 2021, England","volume":"26","author":"Powell","year":"2021","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jinf.2022.01.038_bib0007","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: inital reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0009","first-page":"1212","article-title":"Heterologous prime\u2013boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0011","unstructured":"Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England. Amirthalingam, Gayatri, et\u00a0al. 2021, medRxiv 2021.07.26.21261140."},{"key":"10.1016\/j.jinf.2022.01.038_bib0012","series-title":"COVID-19 Vaccinations","year":"2021"},{"key":"10.1016\/j.jinf.2022.01.038_bib0013","unstructured":"Public Health England. Evaluation of Roche Elecsys Anti-SARS-CoV-2 S serology assay for the detection of anti-SARS-CoV-2 S antibodies. 2020."},{"key":"10.1016\/j.jinf.2022.01.038_bib0014","unstructured":"Evaluation of Roche Elecsys Anti-SARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies. 2020."},{"key":"10.1016\/j.jinf.2022.01.038_bib0015","unstructured":"Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off. Whitaker, Heather J, et\u00a0al. 26 October 2021, MedRxiv."},{"key":"10.1016\/j.jinf.2022.01.038_bib0016","doi-asserted-by":"crossref","unstructured":"Heterologous ChAdOx1 nCoV-19\/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Benning, L., et\u00a0al. 8, August 2021, Vol. 9, p. 857.","DOI":"10.3390\/vaccines9080857"},{"key":"10.1016\/j.jinf.2022.01.038_bib0017","unstructured":"Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. Andrews, N., et\u00a0al. 15 November 2021, medRxiv."},{"key":"10.1016\/j.jinf.2022.01.038_bib0018","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jinf.2022.01.038_bib0019","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2022.01.038_bib0020","unstructured":"GAVI The Vaccine Alliance. There are four types of COVID-19 vaccines: here's how they work. [Online] [Cited: 21 10 2021.] https:\/\/www.gavi.org\/vaccineswork\/there-are-four-types-covid-19-vaccines-heres-how-they-work."},{"key":"10.1016\/j.jinf.2022.01.038_bib0021","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstrom","year":"2021","journal-title":"The Lancet Europe"},{"key":"10.1016\/j.jinf.2022.01.038_bib0022","unstructured":"United States Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. 2021. FDA News Release."},{"key":"10.1016\/j.jinf.2022.01.038_bib0023","unstructured":"Serological responses to COVID-19 booster vaccine in England. Ireland, G., et\u00a0al. 24 November 2021, MedRxiv."},{"key":"10.1016\/j.jinf.2022.01.038_bib0024","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"The Lancet"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016344532200055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016344532200055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:34:49Z","timestamp":1759008889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016344532200055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S016344532200055X"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2022.01.038","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.14.21267562","asserted-by":"object"}]},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2022.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}